Fulcrum Therapeutics and the FSHD Clinical Trial Research Network Announce Clinical Trial Readiness Study

May 21, 2018

Cambridge, Mass., May 21, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, and the FSHD Clinical Trial Research Network (CTRN) today announced the initiation of a clinical trial readiness study. The aim of the study is to help standardize a set of tools and measurements for future Facioscapulohumeral muscular dystrophy (FSHD) clinical drug trials.

CTRN is currently recruiting up to 160 FSHD patients across seven locations across the U.S. For additional study details, please visit the FSH Society website.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.


Sarah Sutton
Ten Bridge Communications
[email protected]